Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Down 29.3% in October

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 148,700 shares, a decline of 29.3% from the September 30th total of 210,400 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 381,100 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 381,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.0% of the company’s shares are short sold.

Chugai Pharmaceutical Price Performance

OTCMKTS CHGCY opened at $22.45 on Wednesday. The stock has a market capitalization of $73.88 billion, a P/E ratio of 28.06 and a beta of 0.64. The business has a 50 day simple moving average of $22.95 and a 200 day simple moving average of $24.40. Chugai Pharmaceutical has a one year low of $19.50 and a one year high of $31.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The firm had revenue of $2.26 billion for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. Equities analysts expect that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.